The regulatory landscape of precision oncology laboratory medicine in the United States - Perspective on the past 5 years and considerations for future regulation

Eric Q Konnick

doi:10.1016/j.plabm.2020.e00172

The regulatory landscape of precision oncology laboratory medicine in the United States - Perspective on the past 5 years and considerations for future regulation

Pract Lab Med. 2020 Aug:21:e00172. doi: 10.1016/j.plabm.2020.e00172. Epub 2020 May 30.

Author

Eric Q Konnick¹

Affiliation

¹ Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.

Abstract

The regulatory landscape for precision oncology in the United States is complicated, with multiple governmental regulatory agencies with different scopes of jurisdiction. Several regulatory proposals have been introduced since the Food and Drug Administration released a draft guidance to regulate laboratory-developed tests in 2014. Key aspects of the most recent proposals and discussion of central arguments related to the regulation of precision oncology laboratory tests provides insight to stakeholders for future discussions related to regulation of laboratory tests.

Keywords: CLIA; CMS; FDA; LDTs; Oncology; Regulation; Testing.

Publication types

Editorial